JP2019521103A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521103A5 JP2019521103A5 JP2018563792A JP2018563792A JP2019521103A5 JP 2019521103 A5 JP2019521103 A5 JP 2019521103A5 JP 2018563792 A JP2018563792 A JP 2018563792A JP 2018563792 A JP2018563792 A JP 2018563792A JP 2019521103 A5 JP2019521103 A5 JP 2019521103A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- cd32b
- cd79b
- dose
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 28
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 28
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 28
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000003844 B-cell-activation Effects 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008958 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010072378 Encephalitis autoimmune Diseases 0.000 claims 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000021330 IgG4-related disease Diseases 0.000 claims 1
- 208000037142 IgG4-related systemic disease Diseases 0.000 claims 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000032580 NMDA receptor encephalitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000029188 anti-NMDA receptor encephalitis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022093028A JP2022120061A (ja) | 2016-06-07 | 2022-06-08 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
| JP2024071096A JP2024102146A (ja) | 2016-06-07 | 2024-04-25 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346717P | 2016-06-07 | 2016-06-07 | |
| US62/346,717 | 2016-06-07 | ||
| US201662432328P | 2016-12-09 | 2016-12-09 | |
| US62/432,328 | 2016-12-09 | ||
| PCT/US2017/036079 WO2017214096A1 (en) | 2016-06-07 | 2017-06-06 | Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022093028A Division JP2022120061A (ja) | 2016-06-07 | 2022-06-08 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
| JP2024071096A Division JP2024102146A (ja) | 2016-06-07 | 2024-04-25 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521103A JP2019521103A (ja) | 2019-07-25 |
| JP2019521103A5 true JP2019521103A5 (enExample) | 2020-06-18 |
Family
ID=60578080
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563792A Pending JP2019521103A (ja) | 2016-06-07 | 2017-06-06 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子の使用方法 |
| JP2022093028A Pending JP2022120061A (ja) | 2016-06-07 | 2022-06-08 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
| JP2024071096A Pending JP2024102146A (ja) | 2016-06-07 | 2024-04-25 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022093028A Pending JP2022120061A (ja) | 2016-06-07 | 2022-06-08 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
| JP2024071096A Pending JP2024102146A (ja) | 2016-06-07 | 2024-04-25 | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190322741A1 (enExample) |
| EP (1) | EP3464378A4 (enExample) |
| JP (3) | JP2019521103A (enExample) |
| KR (3) | KR20190016079A (enExample) |
| CN (1) | CN109311990A (enExample) |
| AU (1) | AU2017278329B2 (enExample) |
| BR (1) | BR112018075303A2 (enExample) |
| MX (2) | MX2018015265A (enExample) |
| RU (1) | RU2022101891A (enExample) |
| TW (1) | TW201742633A (enExample) |
| WO (1) | WO2017214096A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101997A1 (es) * | 2014-09-26 | 2017-01-25 | Macrogenics Inc | Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos |
| ES2987333T3 (es) | 2016-10-26 | 2024-11-14 | Univ Leland Stanford Junior | Regiones bisagra de inmunoglobulina modificadas para reducir la hemaglutinación |
| CN120022359A (zh) * | 2018-10-03 | 2025-05-23 | 柰裴斯生命科学公司 | 抗cd79抗体及其应用 |
| WO2021022072A1 (en) * | 2019-07-30 | 2021-02-04 | Provention Bio, Inc. | Methods and compositions for reducing immunogenicity by non-depletional b cell inhibitors |
| EP4004052A4 (en) * | 2019-07-30 | 2023-11-01 | Provention Bio, Inc. | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY BY NON-DEPLETED B CELL INHIBITORS |
| EP4132582A4 (en) * | 2020-04-10 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | TARGETED REDUCTION OF ACTIVATED IMMUNE CELLS |
| CA3196540A1 (en) * | 2020-11-01 | 2022-05-05 | Francisco Leon | Methods and compositions for treatment of lupus |
| CA3231174A1 (en) * | 2021-08-02 | 2023-02-09 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-cd79bxcd3 bispecific antibody and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| US11384149B2 (en) * | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
| AU2016207758C1 (en) * | 2015-01-13 | 2020-05-28 | Agresearch Limited | Agricultural composition |
-
2017
- 2017-06-06 KR KR1020197000362A patent/KR20190016079A/ko not_active Ceased
- 2017-06-06 KR KR1020227034973A patent/KR20220143769A/ko not_active Ceased
- 2017-06-06 US US16/307,385 patent/US20190322741A1/en active Pending
- 2017-06-06 RU RU2022101891A patent/RU2022101891A/ru unknown
- 2017-06-06 EP EP17810826.2A patent/EP3464378A4/en active Pending
- 2017-06-06 JP JP2018563792A patent/JP2019521103A/ja active Pending
- 2017-06-06 AU AU2017278329A patent/AU2017278329B2/en active Active
- 2017-06-06 MX MX2018015265A patent/MX2018015265A/es unknown
- 2017-06-06 CN CN201780034851.XA patent/CN109311990A/zh active Pending
- 2017-06-06 KR KR1020257002822A patent/KR20250021614A/ko active Pending
- 2017-06-06 BR BR112018075303-3A patent/BR112018075303A2/pt unknown
- 2017-06-06 WO PCT/US2017/036079 patent/WO2017214096A1/en not_active Ceased
- 2017-06-07 TW TW106118941A patent/TW201742633A/zh unknown
-
2018
- 2018-12-07 MX MX2024005841A patent/MX2024005841A/es unknown
-
2022
- 2022-06-08 JP JP2022093028A patent/JP2022120061A/ja active Pending
-
2024
- 2024-04-25 JP JP2024071096A patent/JP2024102146A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521103A5 (enExample) | ||
| RU2022101891A (ru) | Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств | |
| JP2019511212A5 (enExample) | ||
| JP2017522043A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| US20200069797A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists | |
| JP2018509413A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2016507555A5 (enExample) | ||
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| CA3120096A1 (en) | Cd25 antibodies | |
| JP2018501813A5 (enExample) | ||
| JP2023113636A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| JP2019502676A5 (enExample) | ||
| JP2020500542A5 (enExample) | ||
| JP2016527314A5 (enExample) | ||
| JP2017113004A5 (enExample) | ||
| JP2016508153A5 (enExample) | ||
| JP2016527187A5 (enExample) | ||
| JP2005517384A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2017537972A5 (enExample) | ||
| RU2018122255A (ru) | Полипептиды, ингибирующие cd40l |